Cell-Easy and Toulouse University Hospital obtain IMPD approval for first-in-human clinical trial in systemic sclerosis, using promising allogeneic approach
EU regulatory approval to administer Adipose-derived mesenchymal Stem Cells (ASCs) in patients with ischemic digital ulcers marks key milestone for partners Toulouse, France, November 16, 2023 - Cell-Easy, a French…
Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer.
Toulouse, France, September 21st of 2023 Cell-Easy, a specialized contract development and manufacturing organization (CDMO) in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre as the Chief Scientific…
IUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapy
TOULOUSE, FRANCE, June 22, 2023 IUCT-Oncopole and Cell-Easy SAS (Cell-Easy) announced today the signing of a Memorandum of Understanding to enhance their strategic collaborative relationship and open access to advanced cell-based therapies. This…
Cell Easy appoints CDMO expert Dr. Sebastien Ribault as Independent Board Director, to accelerate its rapid growth.
TOULOUSE, France _ April 10, 2023 Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells…
EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001
TOULOUSE, France & MONTPELLIER, France _ September 22, 2022 Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product,…
The OPTI-STEM consortium led by Cell-Easy to democratize access to cell therapy in France and Europe
Toulouse, La Madeleine, Nancy, France – 28 February, 2022 The OPTI-STEM consortium led by CDMO Cell-Easy receives €7M from the French government and Bpifrance and €800,000 from the Occitanie Region…